Examol

Examol is a computational drug discovery software company that builds AI and physics-driven solutions to deliver molecular-level insights for drug discovery programs. Headquartered in Pittsburgh, PA with a presence in Brooklyn, NY, Examol serves pharmaceutical and biotechnology organizations seeking to understand drug-target interactions at a deeper biophysical level, accelerate lead optimization, and make computational chemistry workflows scalable and accessible across entire research teams.

The company combines scientific rigor with modern cloud architecture, offering both software platforms and expert drug discovery services. Examol's approach centers on structure-based and dynamics-optimized discovery, going beyond static models to reveal the molecular mechanisms that drive drug efficacy and selectivity.

Biophysics Solutions

• Unbinding Dynamics: Examol enables scientists to visualize and quantify ligand-protein unbinding pathways using pioneering simulation methods that access timescales traditional molecular dynamics (MD) cannot reach, uncovering dynamical drugging opportunities that static models miss.
• Kinetics-Based Discovery: The platform supports the design of compounds with optimized residence times by identifying the structural features that control binding kinetics, helping improve in vivo efficacy and selectivity.
• Advanced Analysis: Examol's expert team interprets complex simulation data and translates biophysical insights into actionable design strategies for challenging targets, including cryptic pocket discovery and molecular kinetics characterization.

Software Solutions

• Cloud-Native Platform: Examol's cloud-native infrastructure allows users to store, search, and analyze small molecule data at scale and with high speed, reducing infrastructure setup time so scientists can focus on designing better therapeutics.
• Computational Chemistry Workflows: The platform supports standard computational workflows including docking, molecular dynamics (MD), and free energy perturbation (FEP). Users can share workflows with teammates, scale analyses to large compound libraries, and automate repetitive tasks.
• User Augmentation: Examol provides intuitive interfaces designed for scientists rather than programmers, including a web UI, an AI assistant, and JupyterHub integration, making advanced computational methods accessible to the full research team regardless of programming expertise.

Drug Discovery Services and Partnerships

• Drug Discovery Services: Examol's team conducts specialized investigations of customer targets and compounds, leveraging advanced biophysics to enhance target characterization and support lead optimization programs.
• Strategic Partnerships: The company offers co-development partnerships for strategic discovery programs, bringing its computational expertise to address the most challenging drug discovery problems faced by its partners.
• Proven Collaboration: Examol has partnered with organizations such as Psivant Therapeutics, where its computational chemistry and cloud computing capabilities helped overcome previously intractable simulation challenges and accelerated efforts to drug difficult inflammation and immunology targets.

Company Background and Support

• Examol is composed of a multidisciplinary team of scientists, software engineers, and chemists united by a mission to unlock molecular mechanisms that transform drug discovery and accelerate the development of life-changing therapeutics.
• The company's mission is backed by venture capital from leading investors and supported through participation in prestigious accelerator programs.
• Examol operates from offices in Pittsburgh, PA and Brooklyn, NY (Newlab), and can be reached at [email protected] for inquiries about computational workflows, data infrastructure, and molecular-level drug understanding.

Examol represents a convergence of cutting-edge biophysics, cloud-native software engineering, and deep scientific expertise, making it a compelling partner for life sciences organizations looking to push the boundaries of small molecule drug discovery.